<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035135</url>
  </required_header>
  <id_info>
    <org_study_id>ANX005-GBS-03</org_study_id>
    <nct_id>NCT04035135</nct_id>
  </id_info>
  <brief_title>A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)</brief_title>
  <official_title>A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ResearchPoint Global</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi center, open-label, study of ANX005 in combination with IVIg in&#xD;
      subjects diagnosed with GBS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll approximately 12 subjects into one cohort, with subjects receiving 75&#xD;
      mg/kg of ANX005, a dose shown to be safe and well-tolerated as monotherapy and that provides&#xD;
      a meaningful level of exposure to be tested in combination with IVIg. Dosing of IVIg will be&#xD;
      administered as is the current standard of care (0.4 g/kg/day x 5 days) and ANX005 will be&#xD;
      administered concurrently, beginning on Day 1 or 2 of the treatment period. Subjects will be&#xD;
      followed for 6 months after treatment for observation and evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Actual">May 19, 2021</completion_date>
  <primary_completion_date type="Actual">May 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label combination treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ANX005 when administered in combination with IVIg: incidence of TEAEs, SAEs, AE's</measure>
    <time_frame>6 months</time_frame>
    <description>As measured by incidence of TEAEs, SAEs, AE's related to ANX005, SAE's related to ANX005, Grade 3 or higher AEs, Grade 3 or higher AEs related to ANX005, AEs leading to study or treatment discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ANX005 when administered in combination with IVIg</measure>
    <time_frame>3 months</time_frame>
    <description>As measured by ANX005 serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of ANX005 when administered in combination with IVIg</measure>
    <time_frame>4 months</time_frame>
    <description>As measured by CH50 and C1q serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values and change from baseline in Guillain-Barré Syndrome Disability Score (GBS-DS) by visit</measure>
    <time_frame>6 months</time_frame>
    <description>The 6-point Guillain-Barré Syndrme Disability Score (GBS-DS) is a widely accepted and easily obtainable scoring system used to assess functional status of GBS subjects. The score is as follows: 0 = Healthy, 1 = Minor symptoms and capable of running, 2 = Able to walk independently 10 meters or more but unable to run, 3=Able to walk more than 10 meters across an open space with help, 4 = Bedridden or chair bound, 5 = Needing mechanical ventilation, 6 = death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Guillain-Barré Syndrome</condition>
  <arm_group>
    <arm_group_label>Open Label Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One (1) dose of ANX005, 75 mg/kg, will be administered IV. IVIg, 0.4 g/kg, will be administered for 5 consecutive Days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX005</intervention_name>
    <description>investigational drug</description>
    <arm_group_label>Open Label Treatment Arm</arm_group_label>
    <other_name>Anti C1q Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin</intervention_name>
    <description>investigational drug</description>
    <arm_group_label>Open Label Treatment Arm</arm_group_label>
    <other_name>IVIg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of GBS according to the National Institute of Neurological Disorders and&#xD;
             Stroke Diagnostic Criteria for Guillain Barré Syndrome&#xD;
&#xD;
          -  Onset of GBS-related weakness ≤14 days prior to infusion&#xD;
&#xD;
          -  GBS-DS score of 3, 4, or 5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant findings that may interfere with the conduct of the study or&#xD;
             the interpretation of the data&#xD;
&#xD;
          -  Be at risk of suicide or self-harm&#xD;
&#xD;
          -  Received previous treatment with plasma exchange for GBS&#xD;
&#xD;
          -  Any diagnosis of a variant of GBS&#xD;
&#xD;
          -  Have a history of anaphylaxis or severe systemic response to immunoglobulin&#xD;
&#xD;
          -  Documented, clinically significant, pre-existing polyneuropathy from another cause&#xD;
&#xD;
          -  Clinically significant intercurrent illness, medical condition, or medical history&#xD;
&#xD;
          -  History of chronic use of steroid or immunosuppressant medication&#xD;
&#xD;
          -  Active alcohol, drug, or substance abuse&#xD;
&#xD;
          -  Females who are pregnant, breast feeding, or unable or unwilling to use highly&#xD;
             effective methods of contraception throughout the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henk-André Kroon, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Annexon, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Neurosciences and Hospital</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>Denmark</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

